MarketCapExport financials
Cyclacel Pharmaceuticals (CYCC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Cyclacel Pharmaceuticals Balance Sheet 2025-1997 | CYCC
Brief overview of Cyclacel Pharmaceuticals's assets and capital
This overview follows the five latest available annual observations between 2021 and 2025.
Assets finished at $8.2 million versus $42.6 million initially, losing -80.8%. The balance sheet contracted.
The growth rates were balanced: assets changed -80.8%, while liabilities changed -74.8%.
The equity ratio reached 83.6% from 87.5%. A high capital share reduces dependence on liabilities.
The period ended with net cash: net debt stood at -$3.5 million. This supports financial flexibility.
Cash equals 42.8% of the balance sheet, compared with 85.8% five periods ago. This is the readily available cushion.
The accumulated result is -$454.4 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall picture
Taken together, the figures indicate acceptable resilience for Cyclacel Pharmaceuticals. The next assessment depends on debt and equity trends.
Annual Balance Sheet Cyclacel Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-3.5 M | - | -3.34 M | -18.2 M | -36.5 M | -32.3 M | -10.7 M | -17.5 M | -23.9 M | -16.5 M | -20.4 M | -24.2 M | -31.1 M | -16.4 M | -24.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt |
2 K | - | 37 K | 106 K | 30 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 1.06 M | 1.19 M | 100 K | 124 K | 130 K | 176 K | 206 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
1.33 M | 6.27 M | 8.16 M | 7.51 M | 5.29 M | 2.49 M | 2.42 M | 4.45 M | 4.11 M | 5.26 M | 5.75 M | 7.49 M | 7.5 M | 9.34 M | 6.5 M | 6.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.34 M | 6.27 M | 8.2 M | 7.62 M | 5.32 M | 3.54 M | 3.61 M | 4.55 M | 4.24 M | 5.39 M | 5.93 M | 7.7 M | 7.5 M | 9.34 M | 6.5 M | 6.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-454 M | -439 M | -428 M | -406 M | -385 M | -366 M | -358 M | -350 M | -343 M | -335 M | -323 M | -309 M | -289 M | -270 M | -257 M | -242 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
8.18 M | 4.09 M | 8.8 M | 28 M | 42.6 M | 36.8 M | 15.3 M | 19.8 M | 26 M | 19.7 M | 24.8 M | 29.4 M | 35.5 M | 19.4 M | 26 M | 31.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
3.5 M | 3.14 M | 3.38 M | 18.3 M | 36.6 M | 33.4 M | 11.9 M | 17.5 M | 23.9 M | 16.5 M | 20.4 M | 24.2 M | 31.1 M | 16.4 M | 24.4 M | 29.5 M | 11.5 M | 24.2 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
6.84 M | -2.17 M | 607 K | 20.4 M | 37.3 M | 33.3 M | 11.7 M | 15.3 M | 21.8 M | 14.3 M | 18.8 M | 21.7 M | 28 M | 10 M | 19.5 M | 24.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
6.84 M | -2.17 M | 607 K | 15.9 M | 37.3 M | 33.3 M | 11.7 M | 15.3 M | 21.8 M | 14.3 M | 18.8 M | 21.7 M | 28 M | 10 M | 19.5 M | 24.9 M | 5.87 M | 20.6 M | 58 M | 53.9 M | 4.12 M | 24 M | 37.6 M | -15.1 M | -2.59 M | 7.98 M | -1.54 M | 2.01 M | -293 K |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Cyclacel Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2 K | 5 K | 10 K | 9 K | - | - | 5 K | 21 K | 37 K | 52 K | 66 K | 80 K | 106 K | 107 K | 113 K | 15 K | 30 K | 44 K | - | 996 K | 1.06 M | 1.06 M | 1.06 M | 1.06 M | 1.19 M | 1.19 M | 1.19 M | 1.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
804 K | 1.06 M | 770 K | 672 K | 6.27 M | 6.35 M | 7.19 M | 8.37 M | 8.2 M | 8.2 M | 6.81 M | 7.42 M | 7.5 M | 4.46 M | 5.14 M | 6.22 M | 5.32 M | 3.64 M | 3.12 M | 3.77 M | 3.54 M | 3.54 M | 3.54 M | 3.54 M | 3.61 M | 3.61 M | 3.61 M | 3.61 M | 4.55 M | 4.55 M | 4.55 M | 4.55 M | 4.24 M | 4.24 M | 4.24 M | 4.24 M | 5.39 M | 5.39 M | 5.39 M | 5.39 M | 5.93 M | 5.93 M | 5.93 M | 5.93 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 9.34 M | 9.34 M | 9.34 M | 9.34 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M |
Retained Earnings |
-455 M | -444 M | -442 M | -440 M | -439 M | -436 M | -434 M | -431 M | -428 M | -423 M | -417 M | -412 M | -406 M | -399 M | -394 M | -389 M | -385 M | -380 M | -375 M | -370 M | -366 M | -366 M | -366 M | -366 M | -358 M | -358 M | -358 M | -358 M | -350 M | -350 M | -350 M | -350 M | -343 M | -343 M | -343 M | -343 M | -335 M | -335 M | -335 M | -335 M | -323 M | -323 M | -323 M | -323 M | -309 M | -309 M | -309 M | -309 M | -289 M | -289 M | -289 M | -289 M | -270 M | -270 M | -270 M | -270 M | -257 M | -257 M | -257 M | -257 M |
Total Assets |
7.56 M | 8.16 M | 4.4 M | 3.73 M | 4.09 M | 5.38 M | 8.19 M | 6.16 M | 8.8 M | 12.5 M | 16.4 M | 22.1 M | 27.5 M | 31 M | 35.3 M | 39.6 M | 42.6 M | 45 M | 46.3 M | 51.8 M | 36.8 M | 36.8 M | 36.8 M | 36.8 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 26 M | 26 M | 26 M | 26 M | 19.7 M | 19.7 M | 19.7 M | 19.7 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 26 M | 26 M | 26 M | 26 M |
Cash and Cash Equivalents |
3.34 M | 3.84 M | 4.28 M | 3.45 M | 3.14 M | 2.98 M | 6 M | 2.8 M | 3.38 M | 5.94 M | 10.2 M | 11.4 M | 18.3 M | 23.7 M | 29.1 M | 29.6 M | 36.6 M | 40.2 M | 43.6 M | 47.8 M | 33.4 M | 33.4 M | 33.4 M | 33.4 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 23.9 M | 23.9 M | 23.9 M | 23.9 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 31.1 M | 31.1 M | 31.1 M | 31.1 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M |
Book Value |
6.76 M | 7.1 M | 3.63 M | 3.06 M | -2.17 M | -970 K | 999 K | -2.21 M | 607 K | 4.3 M | 9.63 M | 14.6 M | 20 M | 26.6 M | 30.2 M | 33.4 M | 37.3 M | 41.4 M | 43.2 M | 48 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 28 M | 28 M | 28 M | 28 M | 10 M | 10 M | 10 M | 10 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M |
Total Shareholders Equity |
6.76 M | 7.1 M | 3.63 M | 3.06 M | -2.17 M | -970 K | 999 K | -2.21 M | 607 K | 4.3 M | 5.14 M | 10.1 M | 15.5 M | 22.1 M | 30.2 M | 33.4 M | 37.3 M | 41.4 M | 43.2 M | 48 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 28 M | 28 M | 28 M | 28 M | 10 M | 10 M | 10 M | 10 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Cyclacel Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
USA
Russia
Niderland
France
Israel
Australia
Danmark
